Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Intradermal Etanercept Improves Discoid Lupus

Key clinical point: Intradermal delivery of etanercept could be a novel way to treat patients with discoid lupus erythematosus (DLE).

Major finding: More than half of patients (56%) achieved at least a 20% reduction in disease activity from baseline.

Study details: A phase 2, open-label, single-arm, “proof-of concept” study in 25 patients with DLE treated with etanercept.

Disclosures: The study was not commercially funded. Dr. Md Yusof had no disclosures. Pfizer provided the study drug free of charge.

Citation:

Md Yusof MY et al. Rheumatology 2019;58(3):poster 244 doi: 10.1093/rheumatology/kez107.060.